VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.19 USD | -0.58% |
|
-1.17% | +3.81% |
| May. 08 | Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 25 | Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing | MT |
Presenter SpeechChi Meng Fong (Analysts)Good afternoon, everyone. Thanks for joining the BofA ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
65.19
USD
Average target price
103.1
USD
Spread / Average Target
+58.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.81% | 7.09B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- PCVX Stock
- News Vaxcyte, Inc.
- Transcript : Vaxcyte, Inc. Presents at BofA Securities 2021 Virtual Health Care Conference, May-13-2021 03